论文部分内容阅读
评价FIGO分期为Ⅲ期或Ⅳ期卵巢癌患者新辅助化疗(NAC)的生存益处和各种治疗因素预后值的确定。以1987～1996年间16 7例在名古屋大学或相关研究所的妇产科接受治疗的Ⅲ期或Ⅳ期卵巢癌患者纳入本研究。其中119例组织学诊断为浆液性囊腺癌。在119例中对96例常规辅助化疗患者和2 3
To evaluate the survival benefit of neoadjuvant chemotherapy (NAC) in patients with FIGO stage Ⅲ or Ⅳ ovarian cancer and to determine the prognostic value of various treatment factors. A total of 167 patients with stage III or IV ovarian cancer undergoing gynecology and obstetrics at Nagoya University or related institutes from 1987 to 1996 were enrolled in this study. 119 cases of histological diagnosis of serous cystadenocarcinoma. In 119 cases of 96 patients with routine adjuvant chemotherapy and 23 patients